A 58-year-old woman with recurrent platinum-resistant ovarian cancer is offered weekly paclitaxel. She previously received 3-weekly paclitaxel as

Question

A 58-year-old woman with recurrent platinum-resistant ovarian cancer is offered weekly paclitaxel. She previously received 3-weekly paclitaxel as first-line. Is there a schedule advantage?

Accepted Answer

Weekly paclitaxel has a different anti-tumour mechanism with improved tolerability compared with 3-weekly dosing

Answer

Only IV paclitaxel has activity as the preferred next management strategy in this patient

Answer

Weekly paclitaxel is investigational as the preferred next management strategy in this patient

Answer

3-weekly is always superior as the preferred next management strategy in this patient

Answer

No difference between weekly and 3-weekly paclitaxel as the preferred next management strategy

Weekly Paclitaxel — SCE Medical Oncology MCQ

A 58-year-old woman with recurrent platinum-resistant ovarian cancer is offered weekly paclitaxel. She previously received 3-weekly paclitaxel as first-line. Is there a schedule advantage?